Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators. In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing’s syndrome). Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation. What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease. The Senior Director, Oncology Marketing is strategic leadership role in preparing for the launch of Corcept’s first oncology product, relacorilant in platinum resistant ovarian cancer. Reporting to the Vice President of Oncology Marketing, this individual will be responsible for driving brand strategy, leading HCP and patient marketing, and ensuring successful launch execution. The ideal candidate brings deep oncology expertise, strategic leadership, and a proven ability to translate customer insights into actionable strategies in a fast-paced, growth stage environment.